As Cabometyx storms to success, Ipsen 'only growing' pledges CMO

15 June 2018

Ipsen (Euronext: IPN) has been in oncology for a long time — since the 1980s in fact. It's one of the field's top 20 companies. But in a market that’s turbulent, spilling over with established titans and up-and-comers alike, how does the French firm manage to maintain its edge?

Sotirios Stergiopoulos is clear: the strength of its pipeline.

Dr Stergiopoulos, an alumni of some of the industry's biggest players including Celgene (Nasdaq: CELG), Bayer (BAYN: DE) and Novartis (NOVN: VX), has served as chief medical officer at Ipsen since late 2016 and is keen to emphasize the run of success his new firm has been experiencing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK